Cargando…
Autofluorescence Imaging of Treatment Response in Neuroendocrine Tumor Organoids
SIMPLE SUMMARY: Gastroenteropancreatic neuroendocrine tumors (GEP-NET) account for roughly 60% of all neuroendocrine tumors, and low/intermediate grade human GEP-NETs have relatively slow growth rates that many laboratory culture methods fail to capture. Patient-derived cancer organoids (PDCOs) are...
Autores principales: | Gillette, Amani A., Babiarz, Christopher P., VanDommelen, Ava R., Pasch, Cheri A., Clipson, Linda, Matkowskyj, Kristina A., Deming, Dustin A., Skala, Melissa C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8070804/ https://www.ncbi.nlm.nih.gov/pubmed/33919802 http://dx.doi.org/10.3390/cancers13081873 |
Ejemplares similares
-
Impact of baseline culture conditions of cancer organoids when determining therapeutic response and tumor heterogeneity
por: DeStefanis, Rebecca A., et al.
Publicado: (2022) -
Colon Cancer Tumorigenesis Initiated by the H1047R Mutant PI3K
por: Yueh, Alexander E., et al.
Publicado: (2016) -
Metabolic Heterogeneity in Patient Tumor-Derived Organoids by Primary Site and Drug Treatment
por: Sharick, Joe T., et al.
Publicado: (2020) -
Patient-derived cancer organoid tracking with wide-field one-photon redox imaging to assess treatment response
por: Gil, Daniel A., et al.
Publicado: (2021) -
Inhibition of B-cell lymphoma 2 family proteins alters optical redox ratio, mitochondrial polarization, and cell energetics independent of cell state
por: Gillette, Amani A., et al.
Publicado: (2022)